RCEL
AVITA Medical·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 3
Bearish signal 0
High Gross Profit Margin
Revenue Beats Expectation
EPS Beats Expectation
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About RCEL
Avita Medical, Inc.
A regenerative medicine company that developing regenerative products for burns, scars and chronic wounds
Healthcare Technology
12/21/1992
06/30/2020
NASDAQ Stock Exchange
260
12-31
Common stock
28159 Avenue Stanford, Suite 220, Valencia, CA 91355
Addressing unmet medical needs in therapeutic skin repair
AVITA Medical, Inc., was established in Australia on December 21, 1992. The company is a regenerative medicine group with technology platforms designed to address unmet medical needs in burns, trauma, chronic wounds, and skin diseases and aesthetic indications, including vitiligo. The company's patented and proprietary platform technology provides innovative therapeutic solutions derived from the regenerative properties of the patient's own skin.
Company Financials
EPS
RCEL has released its 2025 Q3 earnings. EPS was reported at -0.46, versus the expected -0.29142, missing expectations. The chart below visualizes how RCEL has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
RCEL has released its 2025 Q3 earnings report, with revenue of 17.06M, reflecting a YoY change of -12.71%, and net profit of -13.19M, showing a YoY change of 18.62%. The Sankey diagram below clearly presents RCEL's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
